Esmirtazapine

Drug Profile

Esmirtazapine

Alternative Names: Esmirtazapine maleate; ORG-50081; SCH 900265

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Organon
  • Developer Merck & Co
  • Class Dibenzazepines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Insomnia; Vasomotor symptoms

Most Recent Events

  • 01 Mar 2010 Discontinued - Phase-III for Insomnia in Canada (PO)
  • 01 Mar 2010 Discontinued - Phase-III for Insomnia in USA (PO)
  • 01 Mar 2010 Discontinued - Phase-III for Vasomotor symptoms in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top